Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012966976> ?p ?o ?g. }
- W2012966976 endingPage "121" @default.
- W2012966976 startingPage "113" @default.
- W2012966976 abstract "Abstract To overcome drug resistance in ovarian carcinoma, novel resistance mechanisms must be elucidated for clinical application. We purified 2 proteins in the 300 kDa range from cisplatin‐resistant cells (NOS2CR2) by affinity chromatography with cisplatin‐exposed Glutathione Sepharose 4B. The purified proteins were identified as spectrin αII and βII by peptide mass mapping analysis. Western blot analysis detected greater expression of spectrin αII and βII in NOS2CR2 than in wild‐type cells (NOS2). The same result was obtained for spectrin βII expression by immunohistochemical staining. To determine whether spectrin αII and βII contribute to resistance, a drug sensitivity test was performed on SKOV3 ovarian cancer cells transfected with small interfering RNA. Sensitivity to platinum drugs was increased in the expression reduced cells. In a clinical study of five ovarian serous adenocarcinoma cases, tumor specimens taken after treatment with carboplatin stained more strongly for spectrin βII expression than untreated specimens. Fifty‐two tumor specimens from 46 patients with ovarian serous adenocarcinoma were immunohistochemically stained for spectrin βII and scored. Tumors previously treated by chemotherapy scored higher than those not treated. Of 27 cases with detectable residual tumors at the time of surgery, cases scoring 4–6 had shorter progression‐free survival periods after platinum‐based chemotherapy than cases scoring 0–3 ( p = 0.012). The cytoskeleton proteins Spectrin αII and βII contributed to drug resistance by anchoring the GS‐Pt complex to the cell membrane, arresting cisplatin activity. Thus spectrin βII may be a useful predictor of platinum sensitivity in ovarian serous adenocarcinoma." @default.
- W2012966976 created "2016-06-24" @default.
- W2012966976 creator A5021170427 @default.
- W2012966976 creator A5040835999 @default.
- W2012966976 creator A5058903905 @default.
- W2012966976 creator A5069038207 @default.
- W2012966976 creator A5076276952 @default.
- W2012966976 creator A5078859785 @default.
- W2012966976 creator A5081702111 @default.
- W2012966976 creator A5082303876 @default.
- W2012966976 creator A5084402247 @default.
- W2012966976 date "2011-04-25" @default.
- W2012966976 modified "2023-10-18" @default.
- W2012966976 title "Spectrin αII and βII tetramers contribute to platinum anticancer drug resistance in ovarian serous adenocarcinoma" @default.
- W2012966976 cites W1504784308 @default.
- W2012966976 cites W1581414347 @default.
- W2012966976 cites W1974693247 @default.
- W2012966976 cites W1975085160 @default.
- W2012966976 cites W1987318948 @default.
- W2012966976 cites W1997185869 @default.
- W2012966976 cites W2000532930 @default.
- W2012966976 cites W2003428752 @default.
- W2012966976 cites W2017406515 @default.
- W2012966976 cites W2026819768 @default.
- W2012966976 cites W2075028690 @default.
- W2012966976 cites W2084492467 @default.
- W2012966976 cites W2088493888 @default.
- W2012966976 cites W2098861178 @default.
- W2012966976 cites W2101108802 @default.
- W2012966976 cites W2105782281 @default.
- W2012966976 cites W2130941707 @default.
- W2012966976 cites W2131255875 @default.
- W2012966976 cites W2139409822 @default.
- W2012966976 cites W2143219457 @default.
- W2012966976 cites W2157281800 @default.
- W2012966976 cites W2160552978 @default.
- W2012966976 cites W2164741887 @default.
- W2012966976 cites W2169513844 @default.
- W2012966976 cites W2328421677 @default.
- W2012966976 cites W4323874375 @default.
- W2012966976 doi "https://doi.org/10.1002/ijc.25983" @default.
- W2012966976 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21328338" @default.
- W2012966976 hasPublicationYear "2011" @default.
- W2012966976 type Work @default.
- W2012966976 sameAs 2012966976 @default.
- W2012966976 citedByCount "17" @default.
- W2012966976 countsByYear W20129669762012 @default.
- W2012966976 countsByYear W20129669762013 @default.
- W2012966976 countsByYear W20129669762014 @default.
- W2012966976 countsByYear W20129669762015 @default.
- W2012966976 countsByYear W20129669762016 @default.
- W2012966976 countsByYear W20129669762017 @default.
- W2012966976 countsByYear W20129669762019 @default.
- W2012966976 countsByYear W20129669762020 @default.
- W2012966976 countsByYear W20129669762021 @default.
- W2012966976 countsByYear W20129669762023 @default.
- W2012966976 crossrefType "journal-article" @default.
- W2012966976 hasAuthorship W2012966976A5021170427 @default.
- W2012966976 hasAuthorship W2012966976A5040835999 @default.
- W2012966976 hasAuthorship W2012966976A5058903905 @default.
- W2012966976 hasAuthorship W2012966976A5069038207 @default.
- W2012966976 hasAuthorship W2012966976A5076276952 @default.
- W2012966976 hasAuthorship W2012966976A5078859785 @default.
- W2012966976 hasAuthorship W2012966976A5081702111 @default.
- W2012966976 hasAuthorship W2012966976A5082303876 @default.
- W2012966976 hasAuthorship W2012966976A5084402247 @default.
- W2012966976 hasBestOaLocation W20129669761 @default.
- W2012966976 hasConcept C121608353 @default.
- W2012966976 hasConcept C126322002 @default.
- W2012966976 hasConcept C142669718 @default.
- W2012966976 hasConcept C142724271 @default.
- W2012966976 hasConcept C1491633281 @default.
- W2012966976 hasConcept C150173356 @default.
- W2012966976 hasConcept C153911025 @default.
- W2012966976 hasConcept C204232928 @default.
- W2012966976 hasConcept C2776694085 @default.
- W2012966976 hasConcept C2778239845 @default.
- W2012966976 hasConcept C2780427987 @default.
- W2012966976 hasConcept C2781451048 @default.
- W2012966976 hasConcept C50244902 @default.
- W2012966976 hasConcept C502942594 @default.
- W2012966976 hasConcept C55493867 @default.
- W2012966976 hasConcept C71924100 @default.
- W2012966976 hasConcept C86803240 @default.
- W2012966976 hasConceptScore W2012966976C121608353 @default.
- W2012966976 hasConceptScore W2012966976C126322002 @default.
- W2012966976 hasConceptScore W2012966976C142669718 @default.
- W2012966976 hasConceptScore W2012966976C142724271 @default.
- W2012966976 hasConceptScore W2012966976C1491633281 @default.
- W2012966976 hasConceptScore W2012966976C150173356 @default.
- W2012966976 hasConceptScore W2012966976C153911025 @default.
- W2012966976 hasConceptScore W2012966976C204232928 @default.
- W2012966976 hasConceptScore W2012966976C2776694085 @default.
- W2012966976 hasConceptScore W2012966976C2778239845 @default.
- W2012966976 hasConceptScore W2012966976C2780427987 @default.
- W2012966976 hasConceptScore W2012966976C2781451048 @default.
- W2012966976 hasConceptScore W2012966976C50244902 @default.
- W2012966976 hasConceptScore W2012966976C502942594 @default.